Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $71.77M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.20
• Revenue Growth: -71.01%
• EPS Growth: -14.04%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 93,004,600
• 10 Day Avg. Volume: 1,296,511
• 30 Day Avg. Volume: 1,152,489
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.81
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.80
• Price Target Upside: 582.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Caribou Biosciences faces substantial financial challenges, with no revenue, negative earnings, and cash flow issues. These are compounded by bearish technical indicators and a speculative valuation. While the company's low debt levels suggest sound leverage management, this is overshadowed by operational inefficiencies and market uncertainties.

Positive Factors

Financial Position

A cash reserve of $212.5 million provides Caribou with a solid financial runway, enabling operations into the second half of 2027.

Strategic Focus

Caribou's strategic reprioritization focuses on promising oncology programs for CB-010 in large B cell lymphoma and CB-011 in multiple myeloma, enhancing its commercial potential.

Negative Factors

Approval Probability

The probability of approval is notably low for CB-010 at 30% and CB-011 at 20%, raising concerns about regulatory success.

Pipeline Risks

The discontinuation of CB-010 in lupus and CB-012 in acute myeloid leukemia reduces the value derived from Caribou's pipeline.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

How the Company Makes Money

Caribou Biosciences generates revenue through a combination of licensing agreements, partnerships, and development collaborations. The company licenses its proprietary CRISPR-Cas9 technology to other biotech firms and research institutions, which allows them to generate upfront fees, milestone payments, and royalties based on the success of the licensed products. Additionally, Caribou engages in strategic partnerships and collaborations with pharmaceutical companies to co-develop novel therapies, sharing both the costs and potential profits of successful treatments. These collaborations often involve joint research efforts and clinical development programs, enhancing Caribou's ability to bring its therapies to market. Furthermore, any proprietary products developed by Caribou and successfully commercialized can also contribute to direct sales revenue.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences faces significant financial challenges, with no revenue and negative profits. While the balance sheet shows a low debt-to-equity ratio, profitability remains elusive, and cash flow deficits persist, indicating financial instability.

Income Statement

Caribou Biosciences has shown no revenue for the latest year, and its net income has been consistently negative, indicating ongoing financial challenges. The revenue growth rate has been volatile, with significant fluctuations year over year. Margins, such as EBIT and EBITDA, are negative, reflecting persistent operational inefficiencies.

Balance Sheet

The company has a strong equity base compared to its debt, resulting in a low debt-to-equity ratio. However, the negative return on equity indicates that the company is not generating profit from its equity. The equity ratio has been relatively stable, suggesting a solid capital structure despite ongoing losses.

Cash Flow

Caribou Biosciences has negative operating and free cash flows, highlighting cash management issues. The cash flow to net income ratios are not favorable, reflecting cash flow challenges. The company has been reliant on financing activities to cover cash flow deficits.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.99M	34.48M	13.85M	9.60M	12.36M
	Gross Profit
9.99M	-77.60M	10.21M	8.61M	-22.06M
	EBIT
-166.62M	-116.06M	-106.40M	-66.98M	-36.12M
	EBITDA
-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
	Net Income Common Stockholders
-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
209.54M	328.83M	317.04M	413.51M	15.95M
	Total Assets
313.31M	432.21M	373.76M	442.36M	36.05M
	Total Debt
26.49M	27.11M	27.75M	259.00K	1.58M
	Net Debt
10.19M	-24.05M	-30.59M	-240.16M	-14.38M
	Total Liabilities
60.36M	63.81M	72.89M	54.53M	59.48M
	Stockholders Equity
252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow		Free Cash Flow
-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
	Operating Cash Flow
-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
	Investing Cash Flow
86.61M	-68.18M	-93.25M	-176.40M	6.36M
	Financing Cash Flow
16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Neutral. The current price of 0.85 is above the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.99, and below the 200-day MA of 1.70, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 44.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VXRT	54 Neutral	$102.05M	―	-114.71%	―	288.94%	39.45%
Sector *	51 Neutral	$5.35B	3.41	-40.83%	2.89%	18.11%	2.60%
MGNX	50 Neutral	$103.47M	―	-49.85%	―	155.26%	-640.36%
CRBU	38 Underperform	$71.77M	―	-47.99%	―	-71.01%	-14.04%
ZURA	38 Underperform	$96.41M	―	-44.03%	―	―	86.65%
EDIT	33 Underperform	$132.26M	―	-98.10%	―	-58.64%	-40.05%
ELTX	30 Underperform	$79.29M	―	-9999.00%	―	―	27.65%

Caribou Biosciences Corporate Events

Caribou Biosciences Advances CAR-T Therapy Trials

Caribou Biosciences announced the initiation of the GALLOP Phase 1 clinical trial for CB-010 in lupus patients and provided significant updates on its CAR-T cell therapy programs for hematologic malignancies. The company plans to present data from several Phase 1 trials and potentially begin a pivotal Phase 3 trial in 2025, contingent on positive results. These developments are expected to enhance Caribou’s position in the allogeneic CAR-T cell therapy market, offering broader patient access and quicker treatment availability.